MDx Market to Reach $7.8 Billion in 2013, G2 Intelligence Estimates
A new research report from G2 Intelligence estimates the U.S. molecular diagnostics market will total about $7.8 billion in 2013. While demand for molecular testing is expected to increase, driven by declining costs and growing acceptance of the tests in clinical practice, this growth will likely be offset by the implementation of the new molecular pathology Current Procedural Terminology codes, which will impede growth both through lower reimbursement rates as well as decreases in positive coverage decisions by payers. G2 Intelligence used a proprietary market-sizing methodology that integrates different estimation approaches through a “triangulation” of data from diverse sources, including surveys of laboratories, modeling of disease incidence and testing guidelines, secondary market research, and top-down estimates from Medicare resources. Market size estimates, growth rates, and MDx market subsegments were all calculated using this methodology. The seven market subsegments include hematology, women’s health, general infectious disease, inherited genetic diseases, pharmacogenomics, transplant, and blood screening. MDx is defined in the report as including nucleic acid assays utilizing polymerase chain reaction, in situ hybridization, sequencing, microarrays, cytogenetics, electrophoresis, and genomic immunohistochemistry techniques. Though molecular diagnostics represents a small share of the total clinical laboratory testing market, it is the fastest-growing segment. While hospital […]
Associated Data
Subscribe to Clinical Diagnostics Insider to view
Start a Free Trial for immediate access to this article